Zevra Therapeutics (ZVRA) to Release Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) is projected to issue its Q1 2025 quarterly earnings data after the market closes on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $16.96 million for the quarter.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA opened at $7.87 on Friday. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76. The company has a fifty day moving average of $7.52 and a 200-day moving average of $8.07. The company has a market capitalization of $430.32 million, a P/E ratio of -3.99 and a beta of 1.87. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88.

Wall Street Analysts Forecast Growth

ZVRA has been the subject of a number of research reports. Canaccord Genuity Group upped their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. JMP Securities set a $18.00 target price on Zevra Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Finally, Guggenheim lifted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $22.29.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode bought 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The shares were bought at an average cost of $7.96 per share, with a total value of $79,600.00. Following the completion of the purchase, the director now directly owns 40,000 shares of the company’s stock, valued at $318,400. This trade represents a 33.33 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO R. Laduane Clifton sold 11,000 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the transaction, the chief financial officer now owns 51,361 shares in the company, valued at approximately $403,697.46. This represents a 17.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 85,773 shares of company stock worth $674,176 in the last three months. 2.40% of the stock is owned by insiders.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.